Publications by authors named "M Keyaerts"

Claim this Profile
I
Immune modulation following α and β radionuclide therapy targeting fibroblast activation protein-α in a preclinical tumor model.
Hannelore Ceuppens, Kirsten De Ridder, Thomas Ertveldt, Katty Zeven, Wout De Mey, Marleen Keyaerts

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficient α and β radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model.
Hannelore Ceuppens, Ana Rita Pombo Antunes, Laurent Navarro, Thomas Ertveldt, Marion Berdal, Marleen Keyaerts

Eur J Nucl Med Mol Imaging· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and molecular predictors of [F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Antonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Marleen Keyaerts

Eur J Nucl Med Mol Imaging· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generic semi-automated radiofluorination strategy for single domain antibodies: [F]FB-labelled single domain antibodies for PET imaging of fibroblast activation protein-α or folate receptor-α overexpression in cancer.
Herlinde Dierick, Laurent Navarro, Hannelore Ceuppens, Thomas Ertveldt, Ana Rita Pombo Antunes, Marleen Keyaerts

EJNMMI Radiopharm Chem· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal [F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego

J Nucl Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis